Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Innovotech Inc V.IOT

Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and Minimum Biofilm; Eradication Concentration (MBEC); Antimicrobial and Anti-Biofilm Materials, including TM100, ISO 22196 and USP 51; Customized Antimicrobial Testing, including BEST Assay Testing and Implanted Medical Device Testing; Bacteriophage Testing; and Analytical Capabilities. It also offers MBEC Assay Kits, Order Biofilm Assays and Coated MBEC Assay Lids. Its biofilm research includes The Science of Biofilms, Biofilm Publications and SEM Library. Its antimicrobial silver products include AgreGuard-1 Silver Antimicrobial for Crop Protection and InnovoSIL Antimicrobial Silver Products.


TSXV:IOT - Post by User

Bullboard Posts
Post by DerekForealon Mar 25, 2015 11:49am
95 Views
Post# 23559413

Backlog

BacklogQ3 - "As of the date of this document Innovotech has in hand signed protocols for work that is scheduled to be completed in the last quarter of 2014 that total approximately $280,000"

roughly $175,000(accounts receivable...) +$45,000( revenue incured in quarter) +30,000(in products) =conservatively lets say $250,000 in revenue. 

If with take last quarter gross margin and add a little premium assuming that costs were further reduced - 60% 

Gross profit: $150,000
SGA:            $75,000
R&d:             $20,000
Grant:          ($20,000)
-------------------------------------
                            $75,000
Interrest income: $18,000
--------------------------------------
Net income:         $57,000

Hopefully they will beat these numbers!


GLTA


Bullboard Posts